Bright Grey improves critical illness cancer defintions

Thomas, Paul
May 2013
Money Marketing (Online Edition);5/28/2013, p9
The article reports that protection provider Bright Grey has improved critical illness cancer definition for personal and business protection plans. The additional cover is for chronic lymphocytic leukaemia. Previously, it would only cover chronic lymphocytic leukaemia if it had progressed to stage A.


Related Articles

  • Pattern of Haematological Malignancies in Ilorin, Nigeria: A Ten Year Review. Babatunde, Abiola S.; Amiwero, Christian E.; Olatunji, Philip O.; Durotoye, Idayat A. // Internet Journal of Hematology;2009, Vol. 5 Issue 2, p10 

    A 10 year retrospective survey of haematological malignancies in Ilorin, Nigeria, was carried out based on data from the Records Department and the Cancer Registry of the Morbid Anatomy Department of the University of Ilorin Teaching Hospital. The aim was to determine the current pattern of...

  • Level of education and the risk of lymphoma in the European prospective investigation into cancer and nutrition. Hermann, Silke; Rohrmann, Sabine; Linseisen, Jakob; Nieters, Alexandra; Khan, Aneire; Gallo, Valentina; Overvad, Kim; Tjønneland, Anne; Raaschou-Nielsen, Ole; Bergmann, Manuela M.; Boeing, Heiner; Becker, Nikolaus; Kaaks, Rudolf; Bas Bueno-de-Mesquita, H.; May, Anne M.; Vermeulen, Roel C. H.; Bingham, Sheila; Khaw, Kay-Tee; Key, Timothy J.; Travis, Ruth C. // Journal of Cancer Research & Clinical Oncology;Jan2010, Vol. 136 Issue 1, p71 

    Lymphomas belong to the few cancer sites with increasing incidence over past decades, and only a few risk factors have been established. We explored the association between education and the incidence of lymphoma in the prospective EPIC study. Within 3,567,410 person-years of follow-up, 1,319...

  • Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment. Brian L. Abbott // Oncologist;Jan2006, Vol. 11 Issue 1, p21 

    Chronic lymphocytic leukemia (CLL) is a low-grade B-lineage lymphoid malignancy but may have more heterogeneity than previously thought. Many cases require no treatment at all because of an indolent course, while other patients become symptomatic or develop signs of rapid progression. Treatment...

  • 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Parker, H.; Rose-Zerilli, M. J. J.; Parker, A.; Chaplin, T.; Wade, R.; Gardiner, A.; Griffiths, M.; Collins, A.; Young, B. D.; Oscier, D. G.; Strefford, J. C. // Leukemia (08876924);Mar2011, Vol. 25 Issue 3, p489 

    Historically, genes targeted by recurrent chromosomal deletions have been identified within the smallest genomic region shared in all patients, the minimally deleted region (MDR). However, deletions this small do not occur in all patients and are a simplification of the impact larger...

  • Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Weissmann, S; Roller, A; Jeromin, S; Hernández, M; Abáigar, M; Hernández-Rivas, J M; Grossmann, V; Haferlach, C; Kern, W; Haferlach, T; Schnittger, S; Kohlmann, A // Leukemia (08876924);Dec2013, Vol. 27 Issue 12, p2393 

    A letter to the editor is presented that discusses NOTCH1 mutations in chronic lymphocytic leukemia.

  • Bright Grey extends critical-illness cancer protection. Thomas, Paul // Mortgage Strategy (Online Edition);6/5/2013, p40 

    The article discusses the extension in the critical-illness cancer definition of protection provider Bright Grey for its personal and business protection plans which now have additional cover for chronic lymphocytic leukemia, basal cell carcinoma, and squamous cell carcinoma.

  • R-etodolac (SDX-101) and the related indole–pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells. Lindhagen, Elin; Nissle, Sara; Leoni, Lorenzo; Elliott, Gary; Chao, Qi; Larsson, Rolf; Åleskog, Anna // Cancer Chemotherapy & Pharmacology;Oct2007, Vol. 60 Issue 4, p545 

    SDX-101 is the non-cyclooxygenase 2-inhibiting R-enantiomer of the non-steroid anti-inflammatory drug etodolac, and has anti-tumour activity in chronic lymphocytic leukaemia (CLL). SDX-308 and SDX-309 are more potent, structurally related indole–pyran analogues of SDX-101. The current...

  • The evolving role of Alemtuzumab in management of patients with CLL. Faderl, S.; Coutré, S.; Byrd, J.C.; Dearden, C.; Denes, A.; Dyer, M.J.S.; Gregory, S.A.; Gribben, J.G.; Hillmen, P.; Keating, M.; Rosen, S.; Venugopal, P.; Rai, K. // Leukemia (08876924);Dec2005, Vol. 19 Issue 12, p2147 

    New insights into prognostic markers and the pathophysiology of chronic lymphocytic leukemia (CLL) are beginning to change the concept of CLL treatment. Alemtuzumab has evolved as a potent and effective therapeutic option for patients with CLL. Specifically, alemtuzumab has demonstrated...

  • Chronic Lymphocytic Leukemia Involving the Breast Parenchyma, Mimicker of Invasive Breast Cancer: Differentiation on Breast MRI. Dialani, Vandana; Mani, Kalpana; Johnson, Nicole B. // Case Reports in Medicine;2013, p1 

    Leukemic involvement of the breast is rare, particularly involvement by chronic lymphocytic leukemia (CLL). While concurrent invasive ductal carcinoma and CLL manifesting as a collision tumor in the breast is extremely rare, this association (CLL and carcinoma) has been described in other...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics